Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Patent
1994-08-22
1996-04-30
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
424464, 514884, A61K 920, A61K 948
Patent
active
055122965
ABSTRACT:
A method for inhibiting neuronal damage due to hypoglycemia comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5075321 (1991-12-01), Schreiber
Remington's Pharmaceutical Sciences, Gennaro et al., 18th. Ed., 1990 pp. 682-683.
Draper et al., "Effects of Raloxifene (LY139481 HCl) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Bryant et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. res., Tampa, Sep. 18-22, 1993.
Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. es., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene an Anti-Estrogen, Simulates the Effects of Estogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;". Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109; 1981, 987-989.
Black, L. J. "Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M. K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New benzothiophene derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of 3,4-Dihydro-2(4-methoxyphenl)-1-napthalenyl! 4- 2-pyrrolidinyl) ethoxyl!-phenyl! methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22; 1979, 962-966.
Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo b!thiophene Derivatives Leading to 6-Hydroxy-2-(4-hydroxyphenyl)benzo b!thien-3-yl! 4- 2-(1-piperidinyl)etho xy!-phenyl!methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.
Mestel, New Scientist, p. 10, Nov. 20, 1993.
Singh et al., "Ovariectomy Reduces CLAT Activity and NGF mRNA Levels in the Frontal Cortex and Hippocampus of the Female Sprague-Dawley Rats", Soc. for Neuroscience, Abstract 514.11 1993.
Singh et al., "Estrogen Deprivetion and Replacement Affects Active Avoidance Learning in Femal Sprague-Dawley Rats," Soc. for Neuroscience Abstracts, 18, Abstract 518.19 1992.
Rahling et al., "Effects of Brain-Enhanced Estrogen Delivery System on Tail-skin Temperature of the Rat", Maturitas, 13, 51-63 (1991).
Facts and Comparisons, Sewester et al., Sep. 1990, p. 130.
Eli Lilly and Company
Page Thurman K.
Sales James J.
Spear James M.
LandOfFree
Methods for inhibiting neuronal damage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting neuronal damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting neuronal damage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-626681